Diagnosis and management of aspergillosis in the Netherlands: a national survey

PPA Lestrade; Jacobus Meis; JP Arends; MT van der Beek; E de Brauwer; K van Dijk; SC de Greeff; PJ Haas; CJ Hodiamont; EJ Kuijper; T Leenstra; AE Muller; AMLO Lashof; Bart Rijnders; E Roelofsen; W Rozemeijer; M Tersmette; EM Terveer; CM Verduin; MJHM Wolfhagen; WJG Melchers; PE Verweij

doi:10.1111/myc.12440

Diagnosis and management of aspergillosis in the Netherlands: a national survey

PPA Lestrade
, Jacobus Meis
, JP Arends
, MT van der Beek
, E de Brauwer
, K van Dijk
, SC de Greeff
, PJ Haas
, CJ Hodiamont
, EJ Kuijper
, T Leenstra
, AE Muller
, AMLO Lashof
, Bart Rijnders
, E Roelofsen
, W Rozemeijer
, M Tersmette
, EM Terveer
, CM Verduin
, MJHM Wolfhagen

WJG Melchers, PE Verweij

Medical Microbiology & Infectious Diseases

External organisation

Research output: Contribution to journal › Article › Academic › peer-review

44 Citations (Scopus)

Abstract

A survey of diagnosis and treatment of invasive aspergillosis was conducted in eight University Medical Centers (UMCs) and eight non-academic teaching hospitals in the Netherlands. Against a background of emerging azole resistance in Aspergillus fumigatus routine resistance screening of clinical isolates was performed primarily in the UMCs. Azole resistance rates at the hospital level varied between 5% and 10%, although rates up to 30% were reported in high-risk wards. Voriconazole remained first choice for invasive aspergillosis in 13 out of 16 hospitals. In documented azole resistance 14 out of 16 centres treated patients with liposomal amphotericin B.

Original language	Undefined/Unknown
Pages (from-to)	101-107
Number of pages	7
Journal	Mycoses
Volume	59
Issue number	2
DOIs	https://doi.org/10.1111/myc.12440
Publication status	Published - 2016

Research programs

EMC MM-04-28-04

Access to Document

10.1111/myc.12440

http://hdl.handle.net/1765/91210

Cite this

Lestrade, PPA., Meis, J., Arends, JP., van der Beek, MT., de Brauwer, E., van Dijk, K., de Greeff, SC., Haas, PJ., Hodiamont, CJ., Kuijper, EJ., Leenstra, T., Muller, AE., Lashof, AMLO., Rijnders, B., Roelofsen, E., Rozemeijer, W., Tersmette, M., Terveer, EM., Verduin, CM., ... Verweij, PE. (2016). Diagnosis and management of aspergillosis in the Netherlands: a national survey. Mycoses, 59(2), 101-107. https://doi.org/10.1111/myc.12440

@article{ec4eb0c692cb4d268305bfcb91920859,

title = "Diagnosis and management of aspergillosis in the Netherlands: a national survey",

abstract = "A survey of diagnosis and treatment of invasive aspergillosis was conducted in eight University Medical Centers (UMCs) and eight non-academic teaching hospitals in the Netherlands. Against a background of emerging azole resistance in Aspergillus fumigatus routine resistance screening of clinical isolates was performed primarily in the UMCs. Azole resistance rates at the hospital level varied between 5\% and 10\%, although rates up to 30\% were reported in high-risk wards. Voriconazole remained first choice for invasive aspergillosis in 13 out of 16 hospitals. In documented azole resistance 14 out of 16 centres treated patients with liposomal amphotericin B.",

author = "PPA Lestrade and Jacobus Meis and JP Arends and \{van der Beek\}, MT and \{de Brauwer\}, E and \{van Dijk\}, K and \{de Greeff\}, SC and PJ Haas and CJ Hodiamont and EJ Kuijper and T Leenstra and AE Muller and AMLO Lashof and Bart Rijnders and E Roelofsen and W Rozemeijer and M Tersmette and EM Terveer and CM Verduin and MJHM Wolfhagen and WJG Melchers and PE Verweij",

year = "2016",

doi = "10.1111/myc.12440",

language = "Undefined/Unknown",

volume = "59",

pages = "101--107",

journal = "Mycoses",

issn = "0933-7407",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "2",

}

Lestrade, PPA, Meis, J, Arends, JP, van der Beek, MT, de Brauwer, E, van Dijk, K, de Greeff, SC, Haas, PJ, Hodiamont, CJ, Kuijper, EJ, Leenstra, T, Muller, AE, Lashof, AMLO, Rijnders, B, Roelofsen, E, Rozemeijer, W, Tersmette, M, Terveer, EM, Verduin, CM, Wolfhagen, MJHM, Melchers, WJG & Verweij, PE 2016, 'Diagnosis and management of aspergillosis in the Netherlands: a national survey', Mycoses, vol. 59, no. 2, pp. 101-107. https://doi.org/10.1111/myc.12440

TY - JOUR

T1 - Diagnosis and management of aspergillosis in the Netherlands: a national survey

AU - Lestrade, PPA

AU - Meis, Jacobus

AU - Arends, JP

AU - van der Beek, MT

AU - de Brauwer, E

AU - van Dijk, K

AU - de Greeff, SC

AU - Haas, PJ

AU - Hodiamont, CJ

AU - Kuijper, EJ

AU - Leenstra, T

AU - Muller, AE

AU - Lashof, AMLO

AU - Rijnders, Bart

AU - Roelofsen, E

AU - Rozemeijer, W

AU - Tersmette, M

AU - Terveer, EM

AU - Verduin, CM

AU - Wolfhagen, MJHM

AU - Melchers, WJG

AU - Verweij, PE

PY - 2016

Y1 - 2016

N2 - A survey of diagnosis and treatment of invasive aspergillosis was conducted in eight University Medical Centers (UMCs) and eight non-academic teaching hospitals in the Netherlands. Against a background of emerging azole resistance in Aspergillus fumigatus routine resistance screening of clinical isolates was performed primarily in the UMCs. Azole resistance rates at the hospital level varied between 5% and 10%, although rates up to 30% were reported in high-risk wards. Voriconazole remained first choice for invasive aspergillosis in 13 out of 16 hospitals. In documented azole resistance 14 out of 16 centres treated patients with liposomal amphotericin B.

AB - A survey of diagnosis and treatment of invasive aspergillosis was conducted in eight University Medical Centers (UMCs) and eight non-academic teaching hospitals in the Netherlands. Against a background of emerging azole resistance in Aspergillus fumigatus routine resistance screening of clinical isolates was performed primarily in the UMCs. Azole resistance rates at the hospital level varied between 5% and 10%, although rates up to 30% were reported in high-risk wards. Voriconazole remained first choice for invasive aspergillosis in 13 out of 16 hospitals. In documented azole resistance 14 out of 16 centres treated patients with liposomal amphotericin B.

U2 - 10.1111/myc.12440

DO - 10.1111/myc.12440

M3 - Article

C2 - 26648179

SN - 0933-7407

VL - 59

SP - 101

EP - 107

JO - Mycoses

JF - Mycoses

IS - 2

ER -